![Richard Marshak](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Richard Marshak
Corporate Officer/Principal presso TRISALUS LIFE SCIENCES, INC.
Patrimonio netto: 195 117 $ in data 31/05/2024
Posizioni attive di Richard Marshak
Società | Posizione | Inizio | Fine |
---|---|---|---|
TRISALUS LIFE SCIENCES, INC. | Corporate Officer/Principal | 10/08/2023 | - |
Nephraegis Therapeutics, Inc.
![]() Nephraegis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Nephraegis Therapeutics is a biopharmaceutical company based in Lake Forest, IL. Nephraegis Therapeutics, Inc. focuses on targeting acute kidney injury (AKI) through the development of a family of proprietary drug candidates. The company's lead compound, NPH-022, is an epoxyeicosatrienoic-related compound (EET) with optimized pharmacokinetic properties. The company was founded by Richard B. Marshak, and Bryan F. Cox has been the CEO since 2018. | Direttore/Membro del Consiglio | 01/09/2018 | - |
Fondatore | 01/09/2018 | - | |
Corporate Officer/Principal | 01/09/2018 | - |
Storia della carriera di Richard Marshak
Precedenti posizioni note di Richard Marshak
Società | Posizione | Inizio | Fine |
---|---|---|---|
LF Consulting
![]() LF Consulting Miscellaneous Commercial ServicesCommercial Services LF Consulting specializes in data management and analysis. The private company is based in Sherwood, OR. The company's services include obtaining, transforming, processing, and visualizing data to help clients make informed decisions. | Presidente | 01/01/2013 | 01/06/2022 |
Mount TAM Biotechnologies, Inc.
![]() Mount TAM Biotechnologies, Inc. Pharmaceuticals: MajorHealth Technology Mount TAM Biotechnologies, Inc. is a biopharmaceutical company, which engages in the development of therapeutic products for targeting systemic lupus erythematosus ("SLE"). It also focuses in the discovery and development of novel mTOR inhibitors, with specific emphasis on developing compounds with unique mTORC1:mTORC2 inhibitory profiles. The company was founded by Chester P. Aldridge in November 2011 and is headquartered in Burlington, VT. | Direttore/Membro del Consiglio | 01/03/2016 | 01/10/2019 |
Amministratore Delegato | 01/03/2016 | 01/10/2019 | |
ABBOTT LABORATORIES | Corporate Officer/Principal | 01/01/1999 | 01/01/2013 |
Formazione di Richard Marshak
The University of Chicago Booth School of Business | Masters Business Admin |
University of Pennsylvania | Undergraduate Degree |
Statistiche
Distribuzione geografica
Stati Uniti | 8 |
Posizioni
Corporate Officer/Principal | 3 |
Director/Board Member | 2 |
Chief Executive Officer | 1 |
Settori
Health Technology | 5 |
Consumer Services | 3 |
Commercial Services | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Società quotate in Borsa | 2 |
---|---|
ABBOTT LABORATORIES | Health Technology |
TRISALUS LIFE SCIENCES, INC. | Health Technology |
Aziende private | 3 |
---|---|
Mount TAM Biotechnologies, Inc.
![]() Mount TAM Biotechnologies, Inc. Pharmaceuticals: MajorHealth Technology Mount TAM Biotechnologies, Inc. is a biopharmaceutical company, which engages in the development of therapeutic products for targeting systemic lupus erythematosus ("SLE"). It also focuses in the discovery and development of novel mTOR inhibitors, with specific emphasis on developing compounds with unique mTORC1:mTORC2 inhibitory profiles. The company was founded by Chester P. Aldridge in November 2011 and is headquartered in Burlington, VT. | Health Technology |
LF Consulting
![]() LF Consulting Miscellaneous Commercial ServicesCommercial Services LF Consulting specializes in data management and analysis. The private company is based in Sherwood, OR. The company's services include obtaining, transforming, processing, and visualizing data to help clients make informed decisions. | Commercial Services |
Nephraegis Therapeutics, Inc.
![]() Nephraegis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Nephraegis Therapeutics is a biopharmaceutical company based in Lake Forest, IL. Nephraegis Therapeutics, Inc. focuses on targeting acute kidney injury (AKI) through the development of a family of proprietary drug candidates. The company's lead compound, NPH-022, is an epoxyeicosatrienoic-related compound (EET) with optimized pharmacokinetic properties. The company was founded by Richard B. Marshak, and Bryan F. Cox has been the CEO since 2018. | Health Technology |
- Borsa valori
- Insiders
- Richard Marshak
- Esperienza